ShehlaWynne Ph.D.

Associate

Washington + 1.202.879.3718

Shehla Wynne is an experienced litigator who represents clients in intellectual property matters with a particular focus on biopharmaceutical patent litigation in district courts and at the Patent Trial and Appeal Board (PTAB). She has experience with issues arising under the Hatch-Waxman Act, the Biologics Price Competition and Innovation Act (BPCIA), and the Defend Trade Secrets Act (DTSA). Her experience spans discovery, motion practice, trial, and appeals.

Shehla has significant experience drafting successful dispositive and other critical briefs, resulting in, for example, denial of institution of post-grant proceedings at the PTAB, denial of summary judgment, and denial of a motion for an interlocutory appeal. Shehla's skills extend to oral advocacy; she has presented oral argument in district courts and at the Seventh Circuit.

From 2019 to 2020, Shehla served as a law clerk to the Honorable Kathleen M. O'Malley of the United States Court of Appeals for the Federal Circuit. While in law school, Shehla was executive production editor from 2013 to 2014 of the AIPLA Quarterly Journal, a publication of the American Intellectual Property Law Association. Prior to practicing law, Shehla earned her doctorate in biochemistry and molecular biology at Georgetown University, where her research centered on the molecular mechanisms of prostate cancer cell migration. She has coauthored several peer-reviewed articles in the field of cancer research.

Shehla is actively involved in the Firm's diversity initiatives. She is a co-founder of Desi Writers' Lounge, a nonprofit organization committed to furthering literary awareness in South Asia.

Experience

  • REGENXBIO resolves patent dispute with Aldevron over patented host cells used in gene therapy applicationsJones Day represented plaintiff REGENXBIO Inc. in a patent infringement case brought against Aldevron LLC claiming that without authorization, Aldevron used and manufactured cultured host cells containing recombinant nucleic acid molecules with sequences encoding AAV8 capsid protein(s) and a heterologous non-AAV sequence.
  • REGENXBIO successfully blocks institution of post-grant review of gene therapy patentJones Day successfully defended REGENXBIO, Inc. against a post-grant review (PGR) petition filed by Passage Bio before the U.S. Patent Trial and Appeal Board (PTAB) against one of REGENXBIO's AAV9 patents.
  • Merck unit resolves DJ action involving pneumococcal vaccine patentsJones Day represented Merck Sharp & Dohme Corp. in an action in Delaware district court against Pfizer (through its subsidiaries including Wyeth, LLC) involving several patents on Wyeth’s vaccine technology.
  • Puma Biotechnology asserts patent infringement claims against AstraZeneca's Tagrisso® (osimertinib) products for treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancerJones Day is representing Puma Biotechnology, Inc. in a patent infringement action against defendants for infringement of United States Patent Nos. 10,603,314 and 10,596,162.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Amneal and Kashiv related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against MylanJones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against KVK-Tech and AbhaiJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • Cardinal Health acquires The Harvard Drug Group for $1.115 billionJones Day advised Cardinal Health in its acquisition of The Harvard Drug Group, a distributor of generic pharmaceuticals, over-the-counter medications, and related products to retail, institutional, and alternate care customers from Court Square Capital Partners for $1.115 billion.
  • Purdue Pharma defends against claims of patent infringementJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a patent infringement litigation brought by plaintiff Depomed, Inc., based on Purdue's manufacture and sale of its own patented controlled-release OxyContin(R) pain relief medication.